Sai Life Sciences' Q1 FY 2026-27 Quarterly Results

Result Summary

• Sai Life Sciences Ltd reported a 9.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 10.2%.
• Its expenses for the quarter were down by 3.9% QoQ and up 8.1% YoY.
• The net profit decreased 29.7% QoQ and increased 21.2% YoY.
• The earnings per share (EPS) of Sai Life Sciences Ltd stood at 3.42 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sai Life Sciences Ltd is an emerging contract research, development, and manufacturing organization (CRDMO) that primarily operates within the pharmaceutical industry. The company focuses on offering integrated services to pharmaceutical innovators and generic companies across the globe. Its core offerings include drug discovery, development, and commercial manufacturing services. In recent developments, Sai Life Sciences has been expanding its capacity and capabilities to cater to the growing demand for pharmaceutical services. The company aims to strengthen its position in the global market through strategic investments in R&D and infrastructure.

Revenue

For the first quarter of FY27, Sai Life Sciences Ltd reported a total income of ₹557.83 crores. This represents a decline of 9.7% compared to the previous quarter (Q4FY26), where the company recorded a total income of ₹617.66 crores. However, on a year-over-year basis, the company's total income increased by 10.2% from ₹506.32 crores in Q1FY26. The YoY growth indicates a positive trend in revenue generation compared to the same period last year. The quarter-over-quarter decrease suggests fluctuations that may be typical in the sector due to various operational or market factors.

Profitability

In terms of profitability, Sai Life Sciences Ltd's profit before tax for Q1FY27 amounted to ₹97.97 crores, which is a significant decrease of 29.6% from the previous quarter's ₹139.23 crores. However, when compared to the same quarter last year, there is a notable increase of 21.3% from ₹80.75 crores in Q1FY26. The tax expense for Q1FY27 was ₹24.69 crores, showing a similar trend with a decrease of 29.4% QoQ and an increase of 21.7% YoY. Subsequently, the profit after tax stood at ₹73.28 crores, marking a 29.7% decline from the previous quarter but a 21.2% increase from the previous year. Earnings per share (EPS) followed this pattern with a QoQ drop of 29.8% to ₹3.42, while YoY it rose by 20.8% from ₹2.83.

Operating Metrics

Sai Life Sciences Ltd experienced a decrease in total expenses for Q1FY27, amounting to ₹459.86 crores, which is a 3.9% reduction compared to ₹478.72 crores in Q4FY26. Year-over-year, total expenses increased by 8.1% from ₹425.57 crores in Q1FY26. The reduction in quarterly expenses suggests some level of cost management or operational efficiency improvements, while the annual increase may reflect strategic investments or scaling of operations. These operating metrics, alongside the revenue data, provide insights into the company's financial management and operational dynamics over the reporting periods.